Immunitybio Inc (IBRX)

Currency in USD
6.93
+0.88(+14.55%)
Closed·
6.88-0.05(-0.72%)
·
IBRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.827.03
52 wk Range
1.838.28
Key Statistics
Prev. Close
6.93
Open
6.05
Day's Range
5.82-7.03
52 wk Range
1.83-8.28
Volume
23.19M
Average Volume (3m)
25.66M
1-Year Change
104.4248%
Book Value / Share
-0.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.80
Upside
+70.27%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Immunitybio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Immunitybio Inc Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Compare IBRX to Peers and Sector

Metrics to compare
IBRX
Peers
Sector
Relationship
P/E Ratio
−19.6x−1.0x−0.5x
PEG Ratio
−0.350.050.00
Price/Book
−13.0x1.8x2.6x
Price / LTM Sales
82.7x8.5x3.3x
Upside (Analyst Target)
39.3%139.3%45.0%
Fair Value Upside
Unlock14.5%5.1%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.80
(+70.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy10.00+44.30%8.00MaintainJan 26, 2026
BTIG
Buy9.00+29.87%6.00MaintainJan 22, 2026
Piper Sandler
Buy7.00+1.01%5.00MaintainJan 20, 2026
Jefferies
Buy9.00+29.87%8.00MaintainDec 12, 2025
H.C. Wainwright
Buy8.00+15.44%-MaintainSep 10, 2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.07 / -0.11
Revenue / Forecast
32.06M / 31.88M
EPS Revisions
Last 90 days

IBRX Income Statement

People Also Watch

3.810
SLS
+2.14%
7.580
CRMD
-1.43%
6.47
ENVX
+1.41%
13.950
VTYX
-0.07%

FAQ

What Is the Immunitybio Inc (IBRX) Stock Price Today?

The Immunitybio Inc stock price today is 6.93

What Stock Exchange Does Immunitybio Inc Trade On?

Immunitybio Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immunitybio Inc?

The stock symbol for Immunitybio Inc is "IBRX."

What Is the Immunitybio Inc Market Cap?

As of today, Immunitybio Inc market cap is 6.83B.

What Is Immunitybio Inc's Earnings Per Share (TTM)?

The Immunitybio Inc EPS (TTM) is -0.42.

When Is the Next Immunitybio Inc Earnings Date?

Immunitybio Inc will release its next earnings report on Mar 03, 2026.

From a Technical Analysis Perspective, Is IBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Immunitybio Inc Stock Split?

Immunitybio Inc has split 0 times.

How Many Employees Does Immunitybio Inc Have?

Immunitybio Inc has 673 employees.

What is the current trading status of Immunitybio Inc (IBRX)?

As of Feb 10, 2026, Immunitybio Inc (IBRX) is trading at a price of 6.93, with a previous close of 6.93. The stock has fluctuated within a day range of 5.82 to 7.03, while its 52-week range spans from 1.83 to 8.28.

What Is Immunitybio Inc (IBRX) Price Target According to Analysts?

The average 12-month price target for Immunitybio Inc is USD11.80, with a high estimate of USD24 and a low estimate of USD7. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +70.27% Upside potential.

What Is the IBRX After Hours Price?

IBRX's last after hours stock price is 6.88, the stock has decreased by -0.05, or -0.72%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.